RADIOTHERAPY TREATMENT PLANS WITH RAPIDARC FOR PROSTATE CANCER INVOLVING SEMINAL VESICLES AND LYMPH NODES
RADIOTHERAPY TREATMENT PLANS WITH RAPIDARC FOR PROSTATE CANCER INVOLVING SEMINAL VESICLES AND LYMPH NODES
复制标题
DOI：
10.1016/j.ijrobp.2009.07.1677
复制
发表时间：
2010-03-01
影响因子：
7
通讯作者：
Yin, Fang-Fang
中科院分区：
文献类型：
--
作者：
Yoo, Sua;Wu, Q. Jackie;Yin, Fang-Fang
目的：使用针对高危前列腺癌的 Eclipse 治疗计划系统，比较 RapidArc 计划与传统调强放射治疗 (IMRT) 计划的剂量测定结果和治疗实施效率。材料和方法：本研究包括 10 名患者。主要规划目标体积 (PTV(P)) 包含前列腺、精囊和有边缘的盆腔淋巴结。增强 PTV (PTV(B)) 包含有边缘的前列腺和精囊。总处方剂量为 75.6 Gy（PTV(P) 为 46.8 Gy，PTV(B) 额外为 28.8 Gy；1.8 Gy/分次）。每个 PTV 生成三个计划：多视野 IMRT、一弧 RapidArc (1ARC) 和两弧 RapidArc (2ARC)。结果：在采用 PTV(P) 的初次 IMRT 中，膀胱、直肠和小肠的平均平均剂量分别比初次 1ARC 低 5.9%、7.7% 和 4.3%，比初次 1ARC 低 3.6%、4.8% 和 3.1%。分别比在初级 2ARC 中。在使用 PTV(B) 的加强 IMRT 中，膀胱和直肠的平均剂量比加强 1ARC 低 2.6% 和 4.8%，比加强 2ARC 高 0.6% 和 0.2%。对于主要计划和加强计划，RapidArc 的整体剂量比 IMRT 高 7% 至 9%。使用RapidArc，治疗时间缩短了2-7分钟。结论：对于包括前列腺、精囊和淋巴结在内的PTV，IMRT在膀胱、直肠和小肠的剂量节约方面比RapidArc表现更好。对于包括前列腺和精囊在内的 PTV，具有两个弧的 RapidArc 提供的计划与 IMRT 的计划相当。 RapidArc 的治疗效果更加高效。 (C) 2010 爱思唯尔公司。
Purpose: Dosimetric results and treatment delivery efficiency of RapidArc plans to those of conventional intensity-modulated radiotherapy (IMRT) plans were compared using the Eclipse treatment planning system for high-risk prostate cancer.Materials and Methods: This study included 10 patients. The primary planning target volume (PTV(P)) contained prostate, seminal vesicles, and pelvic lymph nodes with a margin. The boost PTV (PTV(B)) contained prostate and seminal vesicles with a margin. The total prescription dose was 75.6 Gy (46.8 Gy to PTV(P) and an additional 28.8 Gy to PTV(B); 1.8 Gy/fraction). Three plans were generated for each PTV: Multiple-field IMRT, one-are RapidArc (1ARC), and two-arc RapidArc (2ARC).Results: In the primary IMRT with PTV(P), average mean doses to bladder, rectum and small bowel were lower by 5.9%, 7.7% and 4.3%, respectively, than in the primary 1ARC and by 3.6%, 4.8% and 3.1%, respectively, than in the primary 2ARC. In the boost IMRT with PTV(B), average mean doses to bladder and rectum were lower by 2.6% and 4.8% than with the boost 1ARC and were higher by 0.6% and 0.2% than with the boost 2ARC. Integral doses were 7% to 9% higher with RapidArc than with IMRT for both primary and boost plans. Treatment delivery time was reduced by 2-7 minutes using RapidArc.Conclusion: For PTVs including prostate, seminal vesicles, and lymph nodes, IMRT performed better in dose sparing for bladder, rectum, and small bowel than did RapidArc. For PTVs including prostate and seminal vesicles, RapidArc with two arcs provided plans comparable to those for IMRT. The treatment delivery is more efficient with RapidArc. (C) 2010 Elsevier Inc.